Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 20 Mar
    2019

    Update on Alkindi® US development

    US FDA confirms the current clinical and regulatory path for Alkindi: Diurnal on track to submit NDA in Q4 2019

    Read More

  • 25 Feb
    2019

    Diurnal announces submission of Marketing Authorisation Application for Alkindi® and grant of second Alkindi® patent in Israel

    Exemplifies Company’s approach of seeking approval for lead products outside core territories

    Read More

  • 10 Jan
    2019

    Diurnal announces grant of second US patent for Chronocort®

    Method of treatment patent provides additional protection in key US market where Chronocort® has already received two Orphan Drug Designations

    Read More